Multi-step parallel synthesis enabled optimization of benzofuran derivatives as pan-genotypic non-nucleoside inhibitors of HCV NS5B

被引：5

作者：

Xiao, Dong ^{[1
]}

Dai, Xing ^{[1
]}

Liu, Hong ^{[1
]}

He, Shuwen ^{[1
]}

Shi, Zhi-Cai ^{[1
]}

Ludmerer, Steven W. ^{[2
]}

Li, Fangbiao ^{[3
]}

Nargund, Ravi ^{[1
]}

Palani, Anandan ^{[1
]}

机构：

[1] Merck & Co Inc, Dept Med Chem, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA

[2] Merck & Co Inc, Dept Biol, 770 Sumneytown Pike, West Point, PA 19486 USA

[3] Merck & Co Inc, Dept Drug Metab, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2020年 / 30卷 / 07期

关键词：

NS5B NNI inhibitors; Lead optimization; Multi-step parallel libraries; Pan-genotypic potency; HEPATITIS-C VIRUS; MEDICINAL CHEMISTS; DISCOVERY; EPIDEMIOLOGY; POLYMERASE; INFECTION;

D O I：

10.1016/j.bmcl.2020.127004

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

In a lead optimization effort towards NS5B NNI inhibitors, two multi-step parallel libraries were designed and successfully synthesized. Through this effort we discovered compound 9B, which achieved rigorous and delicate balance of inhibition across the common genotypes and mutants with < 10 nM potency. In addition, the bicyclic compounds 9B exhibited improved FASSIF solubility over the tetracyclic compound MK-8876. This strategic approach demonstrated that, even within limited reaction scope, multi-step parallel libraries could provide access to more complex chemical space. This expedient access facilitates diverse, purpose-driven optimization of SAR and physicochemical properties.

引用

页数：6

共 50 条

[41] Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase:: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency
Beaulieu, PL
Bös, M
Bousquet, Y
DeRoy, P
Fazal, G
Gauthier, J
Gillard, J
Goulet, S
McKercher, G
Poupart, MA
Valois, S
Kukolj, G
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (04) : 967 - 971
[42] Structural Basis for Resistance of the Genotype 2b Hepatitis C Virus NS5B Polymerase to Site A Non-Nucleoside Inhibitors
Rydberg, Edwin H.
Cellucci, Antonella
Bartholomew, Linda
Mattu, Marco
Barbato, Gaetano
Ludmerer, Steven W.
Graham, Donald J.
Altamura, Sergio
Paonessa, Giacomo
De Francesco, Raffaele
Migliaccio, Giovanni
Carfi, Andrea
JOURNAL OF MOLECULAR BIOLOGY, 2009, 390 (05) : 1048 - 1059
[43] PATTERNS OF NS5B MUTATIONS IN A 3-DAY CLINICAL TRIAL OF HCV NON-NUCLEOSIDE POLYMERASE INHIBITOR IDX375
McCarville, Joseph
Gillum, Joshua M.
Seifer, Maria
Dumbrava, Vlada-Tatiana
Pietropaolo, Keith
Sullivan-Bolyai, John
Standring, David N.
HEPATOLOGY, 2011, 54 : 542A - 543A
[44] Non-nucleoside inhibitors of NS5B polymerase binding to allosteric sites: 3D-QSAR and molecular docking studies
Cao, Hongyu
Cao, Ran
Zhang, Huabei
Zheng, Xuefang
Gao, Dabin
CURRENT MEDICINAL CHEMISTRY, 2008, 15 (15) : 1462 - 1477
[45] IDENTIFICATION AND CHARACTERIZATION OF PPI-383, A NEXT GENERATION HCV NS5B NON-NUCLEOSIDE INHIBITOR WITH POTENT ACTIVITY AGAINST ALL MAJOR HCV GENOTYPES
Colonno, R.
Huang, N.
Lau, M.
Huang, Q.
Huq, A.
Peng, E.
Bencsik, M.
Zhong, M.
Li, L.
JOURNAL OF HEPATOLOGY, 2012, 56 : S464 - S464
[46] Design, synthesis, and structure-activity relationships of novel imidazo [4,5-c] pyridine derivatives as potent non-nucleoside inhibitors of hepatitis C virus NS5B
Liu, Moyi
Xu, Qiaoling
Guo, Su
Zuo, Ruixi
Hong, Yue
Luo, Yong
Li, Yingxiu
Gong, Ping
Liu, Yajing
BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (09) : 2621 - 2631
[47] Novel 4-Thiazolidinones as Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA Polymerase
Cakir, Gizem
Kucukguzel, Ilkay
Guhamazumder, Rupa
Tatar, Esra
Manvar, Dinesh
Basu, Amartya
Patel, Bhargav A.
Zia, Javairia
Talele, Tanaji T.
Kaushik-Basu, Neerja
ARCHIV DER PHARMAZIE, 2015, 348 (01) : 10 - 22
[48] Non-nucleoside inhibitors of HCV polymerase NS5B. Part 2: Synthesis and structure-activity relationships of benzothiazine-substituted quinolinediones
de Vicente, Javier
Hendricks, Robert T.
Smith, David B.
Fell, Jay B.
Fischer, John
Spencer, Stacey R.
Stengel, Peter J.
Mohr, Peter
Robinson, John E.
Blake, James F.
Hilgenkamp, Ramona K.
Yee, Calvin
Adjabeng, George
Elworthy, Todd R.
Tracy, Jahari
Chin, Elbert
Li, Jim
Wang, Beihan
Bamberg, Joe T.
Stephenson, Rebecca
Oshiro, Connie
Harris, Seth F.
Ghate, Manjiri
Leveque, Vincent
Najera, Isabel
Le Pogam, Sophie
Rajyaguru, Sonal
Ao-Ieong, Gloria
Alexandrova, Ludmila
Larrabee, Susan
Brandl, Michael
Briggs, Andrew
Sukhtankar, Sunil
Farrell, Robert
Xu, Brian
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (13) : 3642 - 3646
[49] Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase (vol 55, pg 2481, 2012)
Sofia, Michael J.
Chang, Wonsuk
Furman, Phillip A.
Mosley, Ralph T.
Ross, Bruce S.
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (07) : 3219 - 3219
[50] Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection
Gane, Edward J.
Stedman, Catherine A.
Hyland, Robert H.
Ding, Xiao
Svarovskaia, Evguenia
Subramanian, G. Mani
Symonds, William T.
McHutchison, John G.
Pang, Phillip S.
GASTROENTEROLOGY, 2014, 146 (03) : 736 - +

← 1 2 3 4 5 →